These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 30053382

  • 21. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH, Lim JY, Choi BH, Choi Y, Choi YH, Park JH, Kim HK.
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [Abstract] [Full Text] [Related]

  • 22. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G, Lou T, Pan J, Ye Z, Yin Z, Li L, Cheng W, Cao Z.
    Aging (Albany NY); 2019 Apr 12; 11(7):2138-2150. PubMed ID: 30981205
    [Abstract] [Full Text] [Related]

  • 23. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
    Song L, Li Y, Li W, Wu S, Li Z.
    J Cell Biochem; 2014 Jul 12; 115(7):1234-42. PubMed ID: 24038379
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
    Pei K, Zhu JJ, Wang CE, Xie QL, Guo JY.
    Eur Rev Med Pharmacol Sci; 2016 Nov 12; 20(22):4697-4704. PubMed ID: 27906433
    [Abstract] [Full Text] [Related]

  • 26. Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell.
    Li N, Zhang F, Li S, Zhou S.
    Biochem Biophys Res Commun; 2014 Feb 21; 444(4):611-6. PubMed ID: 24486548
    [Abstract] [Full Text] [Related]

  • 27. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P, Wu X, Wang X, Huang W, Feng Q.
    Oncotarget; 2016 Jul 12; 7(28):43337-43351. PubMed ID: 27270317
    [Abstract] [Full Text] [Related]

  • 28. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 12; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
    Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM.
    J Cancer Res Clin Oncol; 2010 Apr 12; 136(4):493-502. PubMed ID: 19763620
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. LncRNA MAFG-AS1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/MMP15.
    Li H, Zhang GY, Pan CH, Zhang XY, Su XY.
    Eur Rev Med Pharmacol Sci; 2019 Apr 12; 23(7):2838-2846. PubMed ID: 31002134
    [Abstract] [Full Text] [Related]

  • 33. Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a.
    Tang H, Han X, Li M, Li T, Hao Y.
    Biochimie; 2019 Jul 12; 162():134-143. PubMed ID: 31029744
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.
    Lung Cancer; 2013 May 12; 80(2):216-22. PubMed ID: 23410825
    [Abstract] [Full Text] [Related]

  • 36. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L, Liu X, Ren Y, Zhang J, Chen J, Zhou W, Guo W, Wang X, Chen H, Li M, Yuan X, Zhang X, Yang J, Wu C.
    Cell Death Dis; 2017 Apr 13; 8(4):e2746. PubMed ID: 28406482
    [Abstract] [Full Text] [Related]

  • 37. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS, Zheng YL, Zhao J, Chun X.
    Biomed Pharmacother; 2018 Feb 13; 98():538-544. PubMed ID: 29287202
    [Abstract] [Full Text] [Related]

  • 38. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M, Stordal B.
    Drug Resist Updat; 2011 Jun 13; 14(3):177-90. PubMed ID: 21435938
    [Abstract] [Full Text] [Related]

  • 39. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L, Shang X, Feng Q.
    Cancer Biol Ther; 2019 Jun 13; 20(3):261-271. PubMed ID: 30481109
    [Abstract] [Full Text] [Related]

  • 40. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.
    Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, Lee H.
    Clin Cancer Res; 2010 Nov 01; 16(21):5200-10. PubMed ID: 20959404
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.